Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-11. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
10-formyltetrahydrofolate dehydrogenase is an enzyme that in humans is encoded by the ALDH1L1 gene. The protein encoded by this gene catalyzes the conversion of 10-formyltetrahydrofolate, nicotinamide adenine dinucleotide phosphate (NADP), and water to tetrahydrofolate, NADPH, and carbon dioxide. The encoded protein belongs to the aldehyde dehydrogenase family and is responsible for formate oxidation in vivo. Deficiencies in this gene can result in an accumulation of formate and subsequent methanol poisoning.
== Aim == Green nanotechnology has two goals: producing nanomaterials and products without harming the environment or human health, and producing nano-products that provide solutions to environmental problems. It uses existing principles of green chemistry and green engineering to make nanomaterials and nano-products without toxic ingredients, at low temperatures using less energy and renewable inputs wherever possible, and using lifecycle thinking in all design and engineering stages. In addition to making nanomaterials and products with less impact to the environment, green nanotechnology also means using nanotechnology to make current manufacturing processes for non-nano materials and products more environmentally friendly. For example, nanoscale membranes can help separate desired chemical reaction products from waste materials from plants. Nanoscale catalysts can make chemical reactions more efficient and less wasteful. Sensors at the nanoscale can form a part of process control systems, working with nano-enabled information systems. Using alternative energy systems, made possible by nanotechnology, is another way to "green" manufacturing processes. The second goal of green nanotechnology involves developing products that benefit the environment either directly or indirectly. Nanomaterials or products directly can clean hazardous waste sites, desalinate water, treat pollutants, or sense and monitor environmental pollutants.
10 January – British Post Office scandal: Prime Minister Rishi Sunak announces that emergency legislation would be brought through Parliament to "swiftly exonerate and compensate victims" of the Post Office scandal in England and Wales. First Minister of Scotland Humza Yousaf confirms those in Scotland convicted because of the scandal would also be cleared, and that he would work with the UK government to bring this about. 11 January – The Liberal Democrats ask Ofcom to investigate GB News over alleged bias in its coverage of the Post Office scandal, including what the party's deputy leader, Daisy Cooper, describes as "a fictitious monologue" Nigel Farage delivered about Sir Ed Davey, which she says contained "a number of factual inaccuracies". First Minister of Scotland Humza Yousaf confirms that the Scottish Government would "in essence replicate" the law in England and Wales banning unlicensed ownership of American XL bully dogs. Sunak authorises joint UK–US air strikes against Houthi rebels following attacks against cargo shipping targets in the Red Sea. 12 January – The Liberal Democrats, Scottish National Party and Plaid Cymru call for a recall of parliament to enable a vote on RAF involvement in the air strikes against Houthi rebels in Yemen, since Parliament had already risen for the weekend when Sunak authorised the UK's participation. Sunak authorises talks between the Labour Party and the civil service ahead of a general election later in the year to ensure a smooth transition if Labour becomes the party of government.
Sources: en.wikipedia.org
=== Hyperpyrexia === Hyperpyrexia is an extreme elevation of body temperature which, depending upon the source, is classified as a core body temperature greater than or equal to 40 or 41 °C (104 or 106 °F); the range of hyperpyrexia includes cases considered severe (≥ 40 °C) and extreme (≥ 42 °C). It differs from hyperthermia in that one's thermoregulatory system's set point for body temperature is set above normal, then heat is generated to achieve it. In contrast, hyperthermia involves body temperature rising above its set point due to outside factors. The high temperatures of hyperpyrexia are considered medical emergencies, as they may indicate a serious underlying condition or lead to severe morbidity (including permanent brain damage), or to death. A common cause of hyperpyrexia is an intracranial hemorrhage. Other causes in emergency room settings include malignant catatonia, sepsis, Kawasaki syndrome, neuroleptic malignant syndrome, drug overdose, serotonin syndrome, and thyroid storm.
== Applications == The Information divided AI agents into seven archetypes: business-task agents, for acting within enterprise software; conversational agents, which act as chatbots for customer support; research agents, for querying and analyzing information (such as OpenAI Deep Research); analytics agents, for analyzing data to create reports; software developer or coding agents (such as Cursor); domain-specific agents, which include specific subject matter knowledge; and web browser agents (such as OpenAI Operator). By mid-2025, AI agents were being used in video game development, gambling (including sports betting), cryptocurrency wallets (including cryptocurrency trading and meme coins) and social media. In August 2025, New York Magazine described software development as the most definitive use of AI agents. The Information noted AI coding agents and customer support as the primary uses of AI by businesses by October 2025, although a decline in the expectations of AI capabilities was also noted. In November 2025, The Wall Street Journal reported that few companies that deployed AI agents have received a return on investment.
=== Pharmacokinetics === Aceclidine, when administered ophthalmically, is absorbed primarily through the conjunctival and corneal tissues. Its onset of action is rapid due to efficient local absorption. Systemically, aceclidine undergoes limited metabolism, as its primary site of effect is the eye, thereby minimizing significant systemic exposure. Distribution following ocular administration is predominantly localized, with low risk of systemic accumulation. Excretion details are not extensively characterized, but, like other topical miotic agents, aceclidine is presumed to have minimal systemic bioavailability and is likely eliminated primarily via the local ocular route and normal metabolic pathways.
Sources: en.wikipedia.org
Bill Browder (born 23 April 1964) of Russian Jewish ancestry; author, financier and political activist; CEO and co-founder of Hermitage Capital Management, investment advisor to the Hermitage Fund, which was the largest foreign portfolio investor in Russia; published Red Notice: A True Story of High Finance, Murder, and One Man's Fight for Justice, focusing on his years spent in Russia. A film adaptation written by William Nicholson was reportedly in the works in 2015. A new book by Browder was published on 12 April 2022: Freezing Order: A True Story of Money Laundering, Murder and Surviving Vladimir Putins Wrath. Rivkah Brown; editor of Vashti Media and Novara Media; critic of the concept of the New antisemitism, critic of Israel and Zionism, writes for The Guardian, The Independent, the London Review of Books, The Financial Times and New Statesman. Novara Media (often shortened to Novara) is an independent, left-wing alternative media organisation based in the United Kingdom.
Pilonidal cysts can be itchy and often very painful, and typically occur between the ages of 15 and 35. Although usually found near the coccyx, the condition can also affect the navel, armpit, the cheek, or the genital region, though these locations are much rarer. Signs and symptoms may include:
=== Later medieval works === The Fisher King is a character in Chrétien's Perceval (1180) which is the first of a series of stories and texts on the subject of Perceval and the Grail. In his work, Chrétien did not say how the quester was related to this Fisher King. In later romances it is made clear, in the end, that he is the uncle of the quester. According to Eugène Vinaver, Chretien's work features two Maimed Kings. Parzival was written in 1210 by Wolfram von Eschenbach, thirty years after Perceval. Although a different work, it is strikingly similar to Perceval. The story revolves around the Grail Quest and once again the main character is Perceval (as Parzival). As in Perceval, the story has its protagonist fail to ask the healing question, which results in him Questing for years. However, Parzival differs from Perceval in three major ways. Firstly, the Fisher King is no longer nameless and is called Anfortas. Secondly, Eschenbach thoroughly describes the nature of the wound; it is a punishment for wooing a woman who is not meant for him (every Grail keeper is to marry the woman the Grail determines for him), and it causes him immense pain. Lastly, Parzival comes back to cure the Fisher King. Parzival, unlike its predecessor Perceval, has a definitive ending. The quester is the son of Herzeloyde, who is the sister of Anfortas.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.